Shin Nippon Biomedical Laboratories, Ltd. (FRA:YB3)

Market Cap	320.44M -12.9%
Revenue (ttm)	170.43M +2.2%
Net Income	21.68M -19.3%
EPS	0.52 -19.3%
Shares Out	n/a
PE Ratio	14.78
Forward PE	n/a
Dividend	0.28 (3.60%)
Ex-Dividend Date	Mar 30, 2026

Volume	n/a
Average Volume	251
Open	7.50
Previous Close	7.50
Day's Range	7.50 - 7.50
52-Week Range	7.50 - 10.90
Beta	n/a
RSI	40.34
Earnings Date	May 11, 2026

About FRA:YB3

Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, engages in the pharmaceutical development, transactional research, and medipolis businesses in Japan and internationally. It offers non-clinical testing and non-clinical regulatory consulting for the development of pharmaceuticals, medical devices, or regenerative medicine products, including safety and pharmacology testing, and pharmacokinetic studies. The company also engages in licensing activities for proprietary products which utilize unique intranasal formulation...

• Industry: Commercial Physical and Biological Research
• Founded: 1957
• Employees: 1,532
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: YB3

Financial Performance

In fiscal year 2025, FRA:YB3's revenue was 32.41 billion, an increase of 22.54% compared to the previous year's 26.45 billion. Earnings were 4.92 billion, a decrease of -10.97%.

Financial numbers in JPY